PT
Autoridade da Concorrência

Case details

Print
Merger control
Case reference
Ccent/2023/58 - Pharmanovia / Sanofi
Acquiring
Atnahs Pharma UK Limited
Description
Pharmaceutical company based in the United Kingdom, is indirectly and exclusively controlled by funds known as Triton, which invests in private equity.
Acquired
Sanofi S.A.
Description
Set of assets (brands, registrations, marketing authorizations, supply and manufacturing contracts and inventory) relating to pharmaceutical products based on the active ingredients clobazam, phenobarbital, prochlorperazine and cyamemazine). In Portugal, the assets of Sanofi's pharmaceutical products and related rights relating to the active ingredient clobazam, sold under the trade name Castilium, indicated for the treatment of anxiety.
Sector
  • Health & Pharmaceutical
Activity (NACE)
Applicable legislation
Art. 37(1)(a) (Law 19)
Notification thresholds
Market Share threshold
Type of merger
Conglomerate
Cooperation with sector regulators
Status
Closed
Type of Investigation
Phase 1
AdC’s decision
Non-opposition
Case description

This notification concerns the acquisition of exclusive control of the pharmaceutical product assets of Sanofi S.A. and its affiliates (“Sanofi”), by Atnahs Pharma UK Limited, (“Pharmanovia”).
Timeline
2023-10-11
The AdC issued a non-opposition decision to the merger 58/2023 - Pharmanovia / Sanofi.
2023-09-21
Pharmanovia notifies the acquisition of exclusive control of Sanofi's pharmaceutical product assets.
Click here to see your activities